Acrivon Therapeutics to Present ACR-368 Clinical Data at ESGO Congress
ByAinvest
Friday, Jan 23, 2026 8:15 am ET1min read
ACRV--
Acrivon Therapeutics will present clinical data for ACR-368 at the ESGO 27th Annual Congress in Copenhagen, Denmark. The company believes the data shows a compelling clinical profile for the treatment in a high unmet need area. ACR-368 is a precision medicine discovered and developed using Acrivon's Generative Phosphoproteomics AP3 platform.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet